Skip to main content
NewslettersWatchlist

Alnylam Pharmaceuticals(ALNY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low143.69
Day High147.90
Open:145.21
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why Alnylam Pharmaceuticals Stock Is Sinking Today
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
Motley Fool
2 Growth Stocks That Could Rocket Higher Before the End of 2023
MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence
MarketBeat
3 Stocks to Buy For the COVID Resurgence
Motley Fool
Why Shares of BridgeBio Pharma Skyrocketed This Week
Motley Fool
Why Alnylam Pharmaceuticals Topped the Market Today
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
Business Wire
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
Business Wire
Alnylam Issues 2022 Corporate Responsibility Report
Business Wire
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
MarketBeat
Why Legend Biotech Stock Is Having Its Best Month Yet
Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
Newswire.ca
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Business Wire
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
Business Wire
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
Business Wire
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
Motley Fool
3 Growth Stocks That Could Rocket Higher in 2023
Business Wire
Alnylam Announces Updates to its Board of Directors
Business Wire
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
Business Wire
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Business Wire
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Business Wire
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Business Wire
Alnylam to Webcast Virtual R&D Day
Business Wire
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
Business Wire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Business Wire
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results

Profile

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.